Coamplified and overexpressed genes at ERBB2 locus in gastric cancer

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 548-553

  Varis, Asta ^a   Zaika, Alexander ^b   Puolakkainen, Pauli ^c   Nagy, Balint ^a   Madrigal, Irene ^a   Kokkola, Arto ^c   Väyrynen, Aki ^a   Kärkkäinen, Päivi ^a   Moskaluk, Christopher ^b   El Rifai, Wa'el ^b   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

DARPP32; ERBB2; Gastric cancer; Gene amplification; TOP2A

Indexed keywords

DARPP32 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; TOP2A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 17Q; CHROMOSOME IDENTIFICATION; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GASTROINTESTINAL NEOPLASMS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NERVE TISSUE PROTEINS; PHOSPHOPROTEINS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STOMACH;

EID: 12144287714     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20001     Document Type: Article

References (23)

1. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-25.
2. El-Rifai W, Frierson HF Jr, Moskaluk CA, Harper JC, Petroni GR, Bissonette EA, Jones DR, Knuutila S, Powell SM. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121:592-8.
3. Kokkola A, Monni O, Puolakkainen P, Larramendy ML, Victorzon M, Nordling S, Haapiainen R, Kivilaakso E, Knuutila S. 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer 1997;20:38-43.
4. Varis A, Wolf M, Monni O, Vakkari M, Kokkola A, Moskaluk C, Frierson HF Jr, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002;62:2625-9.
5. Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000;60:4519-25.
6. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, Karhu R, Kallioniemi A. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 2002;35:353-8.
7. Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. 17q gain in neuroblastoma predicts adverse clinical outcome. Med Pediatr Oncol 2001;36:14-9.
8. El-Rifai W, Smith MF Jr, Li G, Beckler A, Carl VS, Montgomery E, Knuutila S, Moskaluk CA, Frierson HF Jr, Powell SM. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 2002;62:4061-4.
9. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy J, Paesmans M, Isola J, Piccart MJ. HER-2 Amplification and topoisomerase II{alpha} gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16.
10. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase II alpha expression in breast cancer: correlation with outcome variables. Mod Pathol 2000;13:542-7.
11. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996;148:2073-82.
12. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol 2001;12:S49-55.
13. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS. Induction of topoisomerase 11 activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001;7:1497-1504.
14. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells: detection by fluorescence in situ hybridization. Am J Pathol 1997;151:761-8.
15. Ooi A, Kobayashi M, Mai M, Nakanishi I. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 1998;78:345-51.
16. Park J, Rhim J, Park S, Kimm S, Kraus M. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 1989;49:6605-9.
17. Yabuki N, Sasano H, Kato K, Ohara S, Toyota T, Nagura H, Miyaike M, Nozaki N, Kikuchi A. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol 1996;149:997-1007.
18. Kim R, Ohi Y, Inoue H, Toge T. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res 1999;19:5393-98.
19. Beckler A, Moskaluk CA, Hampton G, Powell S, Frierson HF Jr, El-Rifai W. Overexpression of DARPP-32 in common adenocarcinomas. Cancer 2003;98:1547-51.
20. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, van de Vijver M. Current perspectives on HER2 testing: a review of national testing quidelines. Mod Pathol 2003;16:173-82.
21. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg A, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999;402:669-71.
22. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984;310:503-5.
23. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999;23:435-47.